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Dysregulated mitophagy and
mitochondrial organization in optic
atrophy due to OPA1 mutations
ABSTRACT
Objective: To investigate mitophagy in 5 patients with severe dominantly inherited optic atrophy
(DOA), caused by depletion of OPA1 (a protein that is essential for mitochondrial fusion), com-
pared with healthy controls.
Methods: Patients with severe DOA (DOA plus) had peripheral neuropathy, cognitive regression,
and epilepsy in addition to loss of vision. We quantified mitophagy in dermal fibroblasts, using 2
high throughput imaging systems, by visualizing colocalization of mitochondrial fragments with
engulfing autophagosomes.
Results: Fibroblasts from 3 biallelic OPA1(2/2) patients with severe DOA had increased mito-
chondrial fragmentation and mitochondrial DNA (mtDNA)–depleted cells due to decreased levels
of OPA1 protein. Similarly, in siRNA-treated control fibroblasts, profound OPA1 knockdown
caused mitochondrial fragmentation, loss of mtDNA, impaired mitochondrial function, and mito-
chondrial mislocalization. Compared to controls, basal mitophagy (abundance of autophago-
somes colocalizing with mitochondria) was increased in (1) biallelic patients, (2) monoallelic
patients with DOA plus, and (3) OPA1 siRNA–treated control cultures. Mitophagic flux was also
increased. Genetic knockdown of the mitophagy protein ATG7 confirmed this by eliminating
differences between patient and control fibroblasts.
Conclusions: We demonstrated increased mitophagy and excessive mitochondrial fragmentation
in primary human cultures associated with DOA plus due to biallelic OPA1 mutations. We pre-
viously found that increased mitophagy (mitochondrial recycling) was associated with visual loss
in another mitochondrial optic neuropathy, Leber hereditary optic neuropathy (LHON). Combined
with our LHON findings, this implicates excessive mitochondrial fragmentation, dysregulated
mitophagy, and impaired response to energetic stress in the pathogenesis of mitochondrial optic
neuropathies, potentially linked with mitochondrial mislocalization and mtDNA depletion.
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GLOSSARY
DOA 5 dominantly inherited optic atrophy; IMM 5 inner mitochondrial membrane; LC3 5 light chain 3; LHON 5 Leber
hereditary optic neuropathy; MMP 5 mitochondrial membrane potential; mtDNA 5 mitochondrial DNA; MFN2 5 mitofusin
2; MTOC 5 microtubule-organizing center; PINK1 5 PTEN-induced putative kinase 1; TMRM 5 tetramethyl rhodamine
methyl ester.
Autosomal dominant optic atrophy (DOA) is the commonest autosomal form of mitochon-
drial optic neuropathy, with most patients harboring pathogenic mutations in the optic
atrophy 1 (OPA1) gene. OPA1 mutations cause dominantly inherited progressive visual
failure in the first 2 decades, secondary to optic nerve neurodegeneration. Strikingly, a sub-
group of patients develops a multisystemic neurologic phenotype, known as DOA plus.
Other obligate OPA1 mutation carriers are visually asymptomatic. The mode of inheritance
is autosomal dominant in the majority of cases, either haploinsufficiency or dominant-
negative, with DOA plus patients frequently harboring missense mutations in the GTPase
domain.
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OPA1 appears to regulate mitochondrial
quality control mediated through mitophagy,1
a specialized type of autophagy.2 Mitophagy is
one among several types of mitochondrial
quality control,3 and the only pathway known
to turn over whole mitochondrial genomes. It
is crucial for normal development4 and allows
dysfunctional mitochondrial DNA (mtDNA)
to be recycled instead of triggering cell death.5
We previously demonstrated increased mi-
tophagy in fibroblasts from patients with Leb-
er hereditary optic neuropathy (LHON).6
This was attenuated by idebenone, which con-
ferred symptomatic improvement.6 To clarify
whether increased mitophagy is an important
feature of mitochondrial optic neuropathies,
we investigated the role ofOPA1 in mitophagy
in primary OPA1 mutant fibroblasts from 5
patients in 3 families with severe DOA plus
phenotypes. We also studied the effects of
siRNA-mediated knockdown of OPA1 in pri-
mary human control fibroblasts. Because
OPA1 deficiency is widely expressed, fibro-
blasts have been extensively used to model
the cellular mechanisms occurring in retinal
ganglion and muscle cells in this multisystem
disease.7,8
METHODS Mitophagy is a sequence of events in which a struc-
ture known as the autophagosome9 forms and engulfs spent mito-
chondria in a process facilitated by microtubule motors. The
autophagosome is then transported towards the cellular
microtubule-organizing center10 (MTOC) and fuses with
lysosomes, ultimately resulting in the degradation of its
enclosed cargo. We therefore quantified mitophagy by counting
autophagosomes, that is, characteristic puncta positive for
microtubule-associated protein 1 light chain 3 (LC3), and
colocalizing with mitochondrial markers.2
Standard protocol approvals, registrations, and patient
consents. Ethics: Patient and control fibroblast lines. Patient
and control samples were obtained with informed consent with
the approval of the UK National Research Ethics Service (South
Central-Berkshire and Newcastle and North Tyneside), or of the
Ethical Committee of the Foundation Carlo Besta Institute of
Neurology, according to the Declaration of Helsinki. Donors
included 5 patients with DOA plus phenotypes, 5 other family
members sharing mutant OPA1 alleles, and 20 normal controls.
Pedigrees of 3 biallelic patients harboring compound heterozy-
gousOPA1mutations (strictly described as semi-dominant11–13) are
presented in figure 1A. A summary of the clinical presentations
and genotypes of all patients (illustrated in figure 1B) are pre-
sented in the table. This includes chronic progressive external
ophthalmoplegia with an apparent defect in mtDNA mainte-
nance14,15 that remains unexplained (DOA plus OPA1[1/2]1
and 2, table). Further details of the clinical presentation, a cranial
MRI scan of the biallelic patients, and the likely effects on protein
are presented in appendix e-1 and figure e-1, A and B, at
Neurology.org. Following the convention of previous authors,13
we designated the 3 biallelic patients DOA plus because each had
clinical and electrophysiologic evidence of both peripheral and
optic neuropathy.
Immunofluorescence and live cell imaging. Cells were pro-
cessed for histochemistry, immunofluorescence, or live staining
with PicoGreen and tetramethyl rhodamine methyl ester
(TMRM) as previously described (appendix e-2). We used 2
high-throughput imaging systems for detecting mitophagy: the
established IN Cell 100016 and ImageStream, which we
validated (figure e-2).
Statistical analysis. Statistical analysis is detailed in appendix e-2.
RESULTS Biallelic OPA1 mutant patients and families.
We studied primary fibroblasts, carrying biallelic
OPA1 mutations, from patients and transmitting rel-
atives belonging to 2 families (see table for an expla-
nation of nomenclature, figure 1A for pedigree, and
appendix e-1 for additional clinical details). The pro-
band of family 1, DOA plus OPA1(2/2)1, is a 17-
year-old boy presenting with a severe OPA1
phenotype (figure 1A). DOA plus OPA1(2/2)1
carries a c.2708_2711delTTAG p.V903Gfs*3
mutation, found in the paternal grandfather, in
trans with a maternal c.661G.A p.E221K change
(OPA1[1/2]1 and N1, respectively, in figure 1A).
In family 2, biallelic patients DOA plus OPA1(2/2)
2 and 3 both had a paternal c.2353delC p.
Q785Sfs*15 and a maternal c.2869C.T, p.H957Y
mutation (figure 1, A and B; see figure e-1B for
PolyPhen analysis). No other relatives were affected.
The frameshift mutation in family 1 is a well-
established pathogenic mutation.17 None of these
mutations involves the GTPase domain of OPA1,
classically implicated in syndromic DOA,13
examples of which were identified in monoallelic
DOA plus families 3 and 4 (table).
Fibroblasts from DOA plus patients have a fragmented
mitochondrial network with occasional mtDNA-depleted
cells. We investigated the cellular phenotype of
probands, transmitting relatives, and controls. We
visualized both mtDNA and mitochondria by using
the DNA-specific dye PicoGreen and the
mitochondrial membrane potential (MMP)–
sensitive dye TMRM.18 The mitochondrial network
had a fragmented morphology in a small minority of
cells from patients DOA plus OPA1(2/2)1–3, but it
was normal in other cells (figure 1C). Using high-
throughput imaging (figure 1D), we showed that
mitochondria in fibroblasts from biallelic and
monoallelic DOA plus patients (DOA plus OPA1
[2/2]1–3 and DOA plus OPA1[1/2]1–2) were
significantly more fragmented than mitochondria
from 6 controls (p 5 0.005 and 0.01, respectively,
figure e-3A). Using PicoGreen to visualize mtDNA,19
we found a significant increase in cells that were
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Figure 1 Genetic analysis of a family with a very severe dominantly inherited optic atrophy (DOA) plus phenotype
(A) Pedigrees of families 1 and 2. (B) OPA1 gene structure. Diagrammatic representation of the OPA1 gene. The diagram indicates the location both of
mutations resulting in DOA plus syndromes as described8 (small symbols) and of the mutations reported in this study (large symbols; highlighting corre-
sponds to pedigree). Mutation type: stars (missense); squares (nonsense); circles (splice site); triangles (deletion). CC 5 coiled-coil domain; GE 5 GTPase
effector domain; UTR5 untranslated region. (C) PicoGreen/tetramethyl rhodamine methyl ester (TMRM) costaining of live fibroblasts from biallelic DOA plus
OPA1(2/2)1–3 patients, and their symptom-free mothers (N1 and OPA1[1/2]2; see A). PicoGreen stains DNA and TMRM is sensitive to mitochondrial
Continued
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depleted of mtDNA in biallelic patients compared to
controls with IN Cell 1000 (p, 0.001, figure 1E). In
all cultures, these mtDNA-depleted cells had
fragmented mitochondria with a lower membrane
potential (figure 1E.a and 1E.b) than control cells.
Intermediate mitochondrial fragmentation and
mtDNA depletion were present in fibroblast
cultures from DOA OPA1(1/2) but not from
non-syndromic DOA (figure e-3A) or the
asymptomatic, obligate carrier relatives of the
biallelic patients.
OPA1 knockdown causes mtDNA depletion and alters
the distribution of mitochondria in control cells. To
determine whether mitochondrial DNA depletion is
a consistent effect of OPA1 knockdown20 and
whether it would be sufficient to affect mitochondrial
function, we then knocked down OPA1 in control
fibroblasts using a pan-OPA1-specific siRNA,21 thus
modeling the reduction in full-length OPA1 protein
in patient cells. Compared to the reduced OPA1
protein levels seen in the patient fibroblasts, the
siRNA achieved a more profound reduction (figure
2A), and knockdown cells underwent fragmentation
and perinuclear clustering of the mitochondrial
network (figure 2B).
Next, we visualized both mtDNA and mitochon-
dria in the OPA1 siRNA-treated cells,18 and found
a marked loss of mtDNA (figure 2C). In these cells,
mitochondria clustered in the perinuclear region (fig-
ure 2, B–D), and often displayed high TMRM fluo-
rescence, suggesting increased MMP or increased
organelle density. We confirmed these findings using
anti-DNA immunoglobulin M/MitoTracker colabel-
ing of mtDNA (figure 2C) and real-time PCR (figure
2E). Despite the considerable mtDNA depletion,
COX activity was largely preserved at 5 days, but
reduced by 14 days (figure 2D).
By using an antibody against pericentrin, we
showed that the perinuclear mitochondrial clusters
consistently colocalized with the MTOC (figure
2F.a). As well as being crucial for neuronal survival
and function, microtubule-dependent transport me-
diates efficient encounters of autophagosomes with
lysosomes,22 which cluster near the nucleus under
conditions such as nutrient deprivation.15,23 A similar
clustering of mitochondria occurs by overexpressing
tau,24 because tau inhibits microtubule-dependent
plus-end-directed transport of mitochondria. Thus,
we hypothesized that clustering of mitochondria at
the MTOC in knockdown cells may be due to either
decreased plus-end or increased minus-end transport
caused by excessive fragmentation and mitophagy. To
test this idea, we exposed cells to microtubule-
disrupting drugs. Nocodazole, which disassembles
microtubules, rescued the perinuclear clustering so
that the distribution of mitochondria resembled that
in control cells (figure 2F.b). Exposure to taxotere
(disrupts MTOC) and cytochalasin D (depolymerizes
actin) disrupted perinuclear mitochondrial clustering,
supporting our assertion that it depends on micro-
tubules and MTOC. For a more detailed explanation,
see figure e-3B. Together, these results demonstrate
that OPA1 knockdown in primary human fibroblasts
causes disruption of the mitochondrial network, par-
tial mtDNA depletion, and microtubule-dependent
rearrangement of the mitochondrial distribution.
High-throughput imaging shows that patient fibroblasts
harbor increased autophagosomes colocalizing with
mitochondria compared to controls. We reasoned that
the depletion of mtDNA associated with OPA1
knockdown could be due either to slowed mtDNA
synthesis or to increased mtDNA turnover and
therefore investigated whether OPA1 insufficiency/
dysfunction had affected mitophagy. We measured
total mitochondrial autophagy irrespective of Parkin
and PINK1 using 2 high-throughput imaging
systems, ImageStream and IN Cell 1000,16 which
are established methods for quantifying autophagy
and mitophagy. In each of these, antibodies to
LC3 and Tom20 are used to immunolabel
autophagosomes and mitochondria, respectively. In
figure e-2D, we show that ImageStream and IN
Cell 1000 techniques are comparable.
Fibroblasts from DOA plus OPA1(2/2)2 and 3
(figure 3A.a) and DOA plus OPA1(2/2)1 (figure
3A.b and 3A.c) patients all harbored significantly
more LC3-positive puncta colocalizing with mito-
chondrial fragments, and hence more mitophagy than
those from the control using ImageStream. Colocal-
ization of the lysosomal marker, LyosID, with LC3
puncta is used to demonstrate autolysosomes, a later
stage of mitophagy than autophagosomes (figure 3A.a
Figure 1 legend, continued:
membrane potential. Nuclei of cells exhibiting mitochondrial fragmentation are marked with an asterisk. PicoGreen panel shows the same field as the high-
magnification TMRM panel. TMRM staining of cells from biallelic DOA plus patients with abnormal mitochondrial fragmentation were often also depleted of
mtDNA (E), but this was more marked in the siRNA-treated cell cultures in figure 2. (D) We used IN Cell 1000 to measure the mean mitochondrial length in
fibroblast cultures, stained either with TMRMand PicoGreen25,26 or with antibody tomitochondrial protein Tom20. Cultures were grown for 3 days in 96-well
plates in triplicate. To quantify the degree of mitochondrial fragmentation, we measured the average mitochondrial length in each cell and plotted a fre-
quency distribution. This shows that while the modal length was similar in both groups, the per cell average mitochondrial length was shorter in biallelic
patients (D.a) than controls (D.b) (see also figure e-3). (E) Cells depleted of mtDNA are increased (E.a) and have a lower membrane potential by TMRM staining
(E.b). Error bars are 1 standard error. Asterisks indicate p, 0.001 compared to controls (2-tailed t test). Each bar represents between 400 and 1,500 cells.
mtDNA 5 mitochondrial DNA.
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and 3A.b, respectively). Increased colocalization of
mitochondria with LC3/LyosID-positive autolyso-
somes supported an increase in mitophagy in these
biallelic patients (figure 3A.c). Figure 3B shows that
the increase in mean level of mitophagy in the group
of all DOA plus patients (combining biallelic and
monoallelic) compared to controls over 4 indepen-
dent experiments was significantly increased (p 5
0.035). It was not increased in nonsyndromic
monoallelic relatives. Analysis of control fibroblasts
treated with OPA1 siRNA also suggested that
mitophagy was increased compared with scramble
siRNA (figure 3C.a). This is consistent with
the increase in LC3-II abundance on Western blot
analysis (figure 3C.b).
Similarly, quantitative fluorescence microscopy
using IN Cell 100016 confirmed that LC3 puncta
colocalizing with mitochondria were increased in
cells from biallelic patients at baseline, compared
to controls (figure 3D). Similar increases in basal
mitophagy were seen in fibroblasts from 2 mono-
allelic DOA plus OPA1(1/2) patients who had
GTPase domain mutations (DOA plus OPA1
[1/2]1 and DOA plus OPA1[1/2]2), but were
comparable to control levels in cells from 5 individ-
uals who had monoallelic OPA1 mutations (N1,
N2, OPA1[1/2]1, OPA1[1/2]2, and DOA
OPA1[1/2]).
Mitophagic flux is increased in fibroblasts from biallelic
DOA plus patients. An increase in autophagosomes
could reflect either increased autophagic activity
or a reduced turnover; we therefore measured mito-
phagic flux. This is defined as the ratio of the mag-
nitude of the increase in counts of puncta
colocalizing with mitochondria over basal levels,
relative to basal mitophagy,2 in a range of culture
conditions and in the presence of lysosomal inhib-
itors. Growing fibroblasts on starvation (culture
in minimal medium) or glucose-free galactose-
based media (henceforth galactose medium) forces
mitochondria to use oxidative phosphorylation and
increases mitophagy.16 These culture conditions
both generated a greater increase in colocalizing
puncta in biallelic patients than in controls on
both ImageStream (figure 3A) and IN Cell 1000
(figures 3D and 4B and not shown). Lysosomal
inhibitors had a similar effect (figures 3, A, B, and
D, and e-4).
Such conditions may also activate autophagy, con-
sistent with the increase in LC3-ll seen on Western
analysis of cells cultured in galactose (figure e-5),
but this increase is less reproducible.
Effect of OPA1 mutations on mitophagy is modulated by
knocking down proteins involved in mitophagy. To con-
firm that the increased colocalization of LC3 puncta
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with mitochondria involved mitophagy, we knocked
down the essential autophagy protein ATG74 (figure
4A). We therefore performed RNAi on fibroblasts
from DOA plus OPA1(2/2)1–3 patients and con-
trols, obtaining a good reduction in ATG7 protein
levels (figure 4A). Both total and colocalizing LC3
puncta were reduced by ATG7 knockdown in all
conditions (p , 0.001, figure 4B), eliminating the
difference between biallelic patients and controls,
both at baseline and after addition of the lysosomal
inhibitors E64D and pepstatin A.
Effect of idebenone. Exposure of fibroblasts to idebenone,
which modulates the increased mitophagy that we dem-
onstrated in LHON,6 had no effect (figure e-4B).
A mitofusin 2 mutation increases mitochondrial
fragmentation and mitophagy. Mitochondrial depo-
larization and ubiquitination are accepted triggers
Figure 2 A reduction in OPA1 leads to rapid loss of mitochondrial DNA (mtDNA)
Control fibroblasts were treated withOPA1 Pan OPA1 or scramble siRNA. (A) Western blot analysis confirms OPA1 levels were efficiently reduced following
siRNA treatment (blot shows 3 days after knockdown). (B) PicoGreen/tetramethyl rhodamine methyl ester (TMRM) costaining of live fibroblasts treated with
OPA1 siRNA shows a marked loss of mtDNA nucleoids (visible as green puncta) compared to treatment with scramble. In all OPA1 knockdown cells with
mitochondrial fragmentation, a noticeable mitochondrial perinuclear clustering was observed (arrows). (C) Anti-DNA/MitoTracker colabeling of OPA1/
scramble siRNA treated fibroblasts (note that this antibody is recognized to label mtDNA more strongly than nuclear DNA). This confirms the findings
presented in B. (D) Cytochrome oxidase (COX) activity, demonstrated by routine histochemistry, is significantly reduced by day 14. In the panel showing COX
at 14 days in the knockdown, the positions of nuclei are marked with asterisks. By day 5, the distribution of both COX and succinate dehydrogenase (SDH)
activity reflect the mitochondrial perinuclear clustering. Figure e-6 shows that mitochondrial fragmentation occurred without loss of cytochrome c or
alteration of cristae at 48 hours. (E) SiRNA to OPA1 significantly reduced the number of nucleoids visualized by PicoGreen (left panel, p , 0.001, 2-tailed
t test) corresponding tomtDNA content of 8%62%of the control. This was confirmed by quantitative PCR14 days after treatment (right panel, p,0.001,
2-tailed t test). (F) Cell biological basis for relocalization of mitochondria during OPA1 knockdown implies altered transport of fragmented mitochondria.
OPA1 knockdown relocates mitochondria to the microtubule organizing center (MTOC), mediated by microtubules and actin. That this is prevented by
overexpression of p50-dynamitin is shown in figure e-3B. (F.a) Anti-pericentrin (MTOC)/mitofillin (mitochondria) staining shows that siRNA to OPA1 causes
relocation of mitochondria to the MTOC in over 90% of cells as opposed to the scrambled siRNA control (see chart). (F.b) The cell biological basis for
relocalization of mitochondria during OPA1 knockdown implies altered transport mediated by microtubules and actin. Upper left: confirms the presence of
perinuclear mitochondrial clusters followingOPA1 knockdown. Upper right: Disassembly of microtubules by nocodazole treatment (5 mM, 24 hours) rescues
the mitochondrial clustering (p , 0.001). Lower left: Taxotere (5 mM, 24 hours) causes assembly and stabilization of microtubules and hence randomly
distributed mitochondrial clusters (3 clusters in one cell each marked with an arrow, p, 0.01). Lower right: Treatment with cytochalasin D (5 mM, 24 hours),
which depolymerizes actin, also redistributes mitochondria away from theMTOC, although a weak perinuclear clustering was still present (p, 0.01). Each of
these experiments was carried out at least 3 times.
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Figure 3 Analysis of primary cultures from biallelic dominantly inherited optic atrophy (DOA) plus OPA1(2/2)
patients demonstrates increased mitophagy compared to an age-matched control
(A) ImageStream analysis of cultured fibroblasts shows that basal mitophagy is significantly increased in DOA plus OPA1
(2/2)2 and DOA plusOPA1(2/2)3 compared with control both at baseline and following treatment with CQ (all p, 0.01, 2-
tailed t test). (A.a) The number of puncta per cell that were positive for light chain 3 (LC3) (representing both autophago-
somes and autolysosomes) and Tom20 (representing mitochondria). These were counted at baseline in control cells, for
comparison with patients DOA plusOPA1(2/2)2 and 3. Exposure to chloroquine (CQ; 25 mM) overnight blocksmitophagy at
this stage by preventing lysosomal acidification increasing the signal, more so in patients than controls. (A.b, A.c) The counts
of puncta that are positive for both LC3 and LysoID (representing only autolysosomes), counted in control cells, for com-
parison with patient DOA plus OPA1(2/2)1. (A.b) The total number of puncta per cell that were positive for the autolyso-
some markers. (A.c) The counts of these autolysosomes that colocalized with mitochondria (hence autolysosomes involved
in mitophagy) for the same dataset. In all cases there were more counts in the patient than the control. Galactose-based
starvation medium increased the number of LC3/LysoID-positive puncta above baseline. Exposure to 25 mM CQ overnight
did not increase the signal, because it prevents progression of autophagosomes to autolysosomes. Error bars are standard
errors (SEs) (technical replicates). Patient values all significantly greater than control p , 0.01 (2-tailed t test). All are
representative of 1 out of 3 independent replicates. (B) A statistical analysis of 4 consecutive ImageStream runs on all the
patients listed in the table along with 6 controls. The output shows increased mitophagy in patients with severe OPA1
mutations (both biallelic and monoallelic, that is, DOA plus OPA1[2/2] and DOA plus OPA1[1/2]) compared with normal
controls (p 5 0.035). We show one bar per patient group, with each bar’s height (y axis) representing the estimated
difference between a particular patient group and controls. The whiskers on a bar represent the SE of the estimated
difference (61 SE is shown); an approximate 95% confidence interval for the patient-control difference could be calculated
as the bar height62 SEs. The p values in the figure are from the test of the null hypothesis that there is no actual difference
Continued
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for mitophagy, in some situations mitophagy being
amplified by ubiquitinylation of the outer membrane
proteins, mitofusin 1 and 2,25 by Parkin, a ubiquitin
ligase recruited to depolarized mitochondria in con-
nection with PTEN-induced putative kinase 1
(PINK1).26,27
Neither mitochondrial depolarization nor ubiqui-
tination were apparent in our patient fibroblasts (fig-
ure 1E and not shown), so we questioned whether
mitochondrial fragmentation was sufficient in itself to
trigger mitophagy. We therefore studied fibroblasts
from a patient with a dominant negative mutation
in another mitochondrial pro-fusion gene, mitofusin
2 (MFN2). These fibroblasts showed increased frag-
mentation of mitochondria compared to controls
(p 5 0.05), associated with increased mitophagy,
both at baseline and after treatment with the lyso-
somal inhibitor, chloroquine (p , 0.02 and 0.001,
respectively, figure 4C).
DISCUSSION We showed that profound loss of
OPA1 has several effects beyond mitochondrial
fragmentation that potentially contribute to the
pathogenesis of DOA and the onset of clinical
disease. These include increased mitophagy, mito-
chondrial mislocalization, and, potentially, mito-
chondrial dysfunction due to mosaic mtDNA
depletion.
We identified 3 patients who each carried one
frameshift mutation in trans with a novel missense
mutation, designated biallelic OPA1. The term Behr
syndrome has been used for other biallelic OPA1
families with severe phenotypes in which a missense
allele, described as hypomorphic, occurs in trans with
a pathogenic allele.28 Furthermore, both frameshift
mutations caused nonsyndromic DOA with incom-
plete penetrance, yet caused DOA plus when com-
bined with a missense mutation.
OPA1 is a transmembrane protein embedded
within the inner mitochondrial membrane (IMM),
involved in mitochondrial dynamics, specifically in
IMM fusion29 and maintenance of cristae. It is pro-
tective against apoptosis30 and neurodegeneration.31
Mutant cells derived from patients with biallelic
OPA1 mutations not only had a lower level of
OPA1 protein, but there was evidence of significant
mitochondrial fragmentation compared with controls
(figure 1D). A small proportion of these cells with
fragmented mitochondria were profoundly depleted
of mtDNA (figure 1, C and E). High-throughput
quantitative imaging revealed that mitochondrial
fragmentation and mtDNA depletion was also
increased in monoallelic DOA plus patients with
dominantly inherited OPA1 mutations involving
the GTPase domain. While OPA1 depletion is
known to cause mtDNA depletion in neurons,32
the association in fibroblasts is novel. In line with
other investigators, fragmentation and mtDNA
depletion (figure 1E) were not present in fibroblast
cultures from nonsyndromic DOA patients, from the
asymptomatic, obligate carrier relatives of biallelic pa-
tients, or from the controls (table).
Previous investigators found that cultured cells
with even severe respiratory chain defects appear to
experience rather small increases in mitophagy33 and
that defects in respiratory chain function, if present in
OPA1 patients,14 are subtle.7 We suggest that these
subtle defects may reflect the increased level of
mtDNA-depleted mitochondria in cells that we
documented. Two high-throughput imaging systems
(ImageStream and IN Cell 1000) provide objective
evidence of increased colocalization of mitochondria
with autophagosomes and autolysosomes. These are
more sensitive and specific for measuring mitophagy
than conventional fluorescence and electron micros-
copy and Western blotting. Both methods showed
Figure 3 legend, continued:
between a patient group and controls. Useful intuition connecting the hypothesis test with the estimated difference is that
a p value , 0.05 corresponds to a 95% confidence interval not overlapping zero. Uncomplicated symptomatic DOA OPA1
(1/2) and asymptomatic OPA1(1/2) were not different from controls (n 5 1, 2, and 6, respectively). Chloroquine 25 mM
overnight CQ significantly increased the number of LC3 puncta colocalizing with the mitochondrial signal in all individuals in
all experiments (p , 0.001). (C) OPA1 knockdown by siRNA also increases mitophagy. (C.a) Bar chart of ImageStream
output shows that siRNA to OPA1 increases mitophagy. The summed area of LC3 puncta that colocalize with mitochondria
(PDH signal) in fibroblasts treated with OPA1 siRNA is greater than in scramble siRNA and the untreated controls (p5 0.05
and p , 0.01, respectively, both 2-tailed t tests). Mitochondrial mean intensity was also reduced by 5% (not shown). Error
bars are SEs (technical replicates). (C.b) In OPA1 knockdown fibroblasts (OPA1 siRNA) compared to untreated (No siRNA)
and siRNA scramble (Scr siRNA) controls, OPA1 levels are reduced and LC3-II levels are substantially increased relative to
actin by the Western blot analysis. (D) Validation of the increased mitophagic flux, using IN Cell 1000 quantitative fluores-
cencemicroscopy. The number of LC3-positive puncta per cell was quantitated in fibroblasts from biallelicOPA1 patients at
baseline and after 2 hours in the presence of lysosomal protease inhibitors (E64D and pepstatin A, labeled E1P) or after 2
hours starvation in minimal medium compared with age-matched controls. (D.a) Per cell count of LC3-positive puncta
colocalizing with mitochondria (p , 0.0001 and p , 0.005 for baseline compared to lysosomal inhibitors or starvation,
respectively). (D.b) Mean number of total LC3-positive puncta per cell. Each patient had significantly higher counts than
control (p, 0.02) in all conditions, except baseline patient DOA plusOPA1(2/2)3 autophagy and baseline patient DOA plus
OPA1(2/2)1 mitophagy. (D.c) The mitophagic flux is increased in biallelic patients relative to controls (the increase in
colocalization during starvation or lysosomal inhibitors, relative to baseline). Error bars are SEs of technical replicates, all
p values 2-tailed t tests. For further evidence of increased mitophagic flux, see figure e-4A.
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that mitophagy is increased at baseline and following
activation of autophagy in biallelic DOA plus fibro-
blasts, and is reduced by knockdown of the autoph-
agy protein ATG7 (figures 4, A and B, and e-2E).
The increased colocalization of mitochondria and au-
tophagosomes represents increased mitophagic flux
(figure e-4). Mitophagy was thus clearly increased
in patients with monoallelic DOA plus and in
severely affected biallelic OPA1 patients, but not sig-
nificantly in our monoallelic unaffected participants
or in mildly affected, nonsyndromic monoallelic
OPA1 patients. The abundance of OPA1 protein
Figure 4 Effect of OPA1 mutations on mitophagy is impaired by knockdown of ATG7 and recapitulated by
a mitofusin 2 (MFN2 )–dominant negative genotype
(A) Western blot analysis confirms that knockdown of ATG7 by siRNA reduced protein abundance relative to actin in both
patient and control cells. ATG7 5 siRNA to ATG7; DOA 5 dominantly inherited optic atrophy; scr 5 scramble; siRNA 5 no
treatment. (B) The number of colocalizing mitochondrial puncta (mitophagy events per cell, measured by IN Cell 1000) is
significantly increased in fibroblasts from biallelic patients compared to controls at baseline (B.a) (p , 0.001) and after
blocking autophagy with lysosomal inhibitors E64D and pepstatin A (E1P, p 5 0.01). (B.b) Adding E64D and pepstatin A
significantly increased the numbers of colocalizing puncta (p , 0.001) compared to baseline. Knockdown of ATG7 protein
by siRNA significantly reduced the colocalizing puncta (p , 0.001) and eliminated the increase in patients over controls.
Cells were treated with siRNA against ATG7 for 48 hours, then the medium was changed and either solvent or lysosomal
inhibitors, E64D, and pepstatin A were added for 3 days. Error bars are standard errors of technical replicates, all p values
2-tailed t tests. (C) The number of mitophagy events per cell (measured by IN Cell 1000) at baseline (C.a) is significantly
increased in fibroblasts from biallelic DOA plus OPA1(2/2) patients (n5 3) and in a patient with a dominant negativeMFN2
mutation compared to control (p , 0.001 and p , 0.02, respectively). After adding chloroquine (C.b), this was significantly
increased in both the DOA plusOPA1(2/2) patients (n5 3) and theMFN2 fibroblasts compared to control (both p, 0.001).
In neither case was the MFN2 significantly different from biallelic DOA plus OPA1(2/2) patients. Error bars are standard
errors of technical replicates, all p values 2-tailed t tests.
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reflected these differences (figure e-5). This is sup-
ported by electron microscopic findings in 2 mouse
models.17,34
Because mitophagy does not appear to increase
bulk turnover of all mitochondrial components,35
its importance has been called into question. It is
the only type of mitochondrial quality control known
to turn over whole mitochondrial genomes. While it
is not clear that OPA1 mutations directly cause
mtDNAmutations or depletion, altering the dynamic
cycle of mitochondrial fission and fusion is likely to
dysregulate mitophagy and impair mitochondrial
quality.36
Our data show that active mitophagy closely re-
flects the phenotypic severity of DOA plus due to
OPA1 depletion (figures 1E, 3B, and e-5). We
suggest 3 ways in which these could be linked
(figure e-7).
First, the increased mitophagy may be driven by
an excess of fragmented mitochondria, potentially
because of a respiratory chain defect that we did not
detect. This could be beneficial or neutral. This
increase is consistent with type 1 mitophagy,37 a sub-
type that is independent of PINK1 and Parkin.37 This
is because we found no evidence of increased ubiq-
uitination (not shown) and no recruitment of the
mitophagy proteins PINK1 and Parkin. It is thus
plausible that increased fragmentation drives type 1
mitophagy.
Further, microtubule-dependent clustering of
mitochondria, which is also apparent in MFN2
knockdown,38 may also disadvantage the cell, repre-
senting a mitophagic traffic jam. For instance, clus-
tering of fragmented mitochondria may mechanically
obstruct axonal transport of functioning mitochon-
dria or prevent mitochondrial responses to stress
(stress-induced mitochondrial hyperfusion39).
Third, activated mitophagy may increase turnover
of mitochondria and mtDNA. We showed that pro-
found OPA1 knockdown in control fibroblasts causes
progressive loss of mtDNA and eventually mitochon-
drial function (figure 2E). Mitophagy may be exces-
sive in retinal ganglion cells of OPA1 patients,
perhaps increasing demand on lysosomal pathways
or causing mtDNA depletion in key locations.
Indeed, OPA1 depletion recapitulates the effects of
the mitophagy-activating drug, phenanthroline. By
disrupting OPA1 processing, this metalloprotease
inhibitor activates mitophagy excessively, depleting
mitochondria and mtDNA and impairing the selec-
tivity for damaged mtDNA.16
The interplay between these mechanisms remains
to be determined (figure e-7). We showed evidence
that OPA1 depletion affects mitochondrial fragmen-
tation, quality control, and likely microtubular trans-
port, all important determinants of mitochondrial
mass,40 neuronal maturation,32 and health.3 These
could underline the known effects of OPA1 depletion
on neural maturation,32 leading to retinal ganglion
cell loss, optic nerve degeneration, and hence visual
failure. In particular, increased mitophagy is impli-
cated in both LHON and syndromic parkinsonism
caused by OPA mutations.8 These add biological
credibility to our suggestion that dysregulated
mitophagy is important in the pathogenesis of mito-
chondrial optic neuropathies.6 If so, drug modulators
of mitophagy may be useful therapies for this group of
disorders.
AUTHOR AFFILIATIONS
From the Nuffield Department of Obstetrics and Gynaecology (C. Liao,
N.A., A.D., K.M., L.V., J.C., E.D., J.P.), The Women’s Centre; Nuf-
field Department of Medicine (K.P., A.K.S.), NIHR Translational
Immunology Laboratory Biomedical Research Centre, Oxford; Depart-
ments of Paediatrics and Ophthalmology and Virtual Academic Unit
(A.W., I.F.), Northampton General Hospital; Institute of Medical Genet-
ics (L.R.) and Cardiff Eye Unit (M.V.), University Hospital of Wales,
Cardiff; Department of Clinical Genetics (J.L.) and Oxford Medical
Genetics Laboratories (C.F.), Churchill Hospital; Nuffield Division of
Clinical Laboratory Sciences (D.J.P.F.); Department of Neuroradiology
(G.Q.), Oxford University Hospitals NHS Trust, UK; Department of
Child Neurology (I.M.) and Division of Molecular Neurogenetics
(C. Lamperti), Carlo Besta Neurological Institute IRCCS; Service of
Neuro-ophthalmology and Eye Electrophysiology (S.B.), The Auxological
Institute IRCCS, Milan, Italy; Department of Ophthalmology (S.M.D.),
John Radcliffe Hospital, Oxford; Wellcome Trust Centre for Mitochon-
drial Research (K.S.S., P.J.F., P.Y.-W.-M.), Institute of Genetic Medi-
cine, Newcastle University, Newcastle upon Tyne; Department of
Comparative Biomedical Sciences (D.E., M.C.), The Royal Veterinary
College, University of London; MRC Centre for Neuromuscular Disor-
ders (M.L., M.M.R.), Department of Molecular Neurosciences, UCL
Institute of Neurology, Queen Square, London; Sheffield Institute for
Translational Neuroscience (H.M.), University of Sheffield; CRUK/
MRC Oxford Institute for Radiation Oncology (R.P.) and Division of
Cardiovascular Medicine, Radcliffe Department of Medicine (M.J.D.),
University of Oxford; UCL Consortium for Mitochondrial Research
(M.C.), London; MRC Mitochondrial Biology Unit (M.Z.), Cambridge;
Newcastle Eye Centre (P.Y.-W.-M.), Royal Victoria Infirmary, Newcastle
upon Tyne, and NIHR Biomedical Research Centre at Moorfields Eye
Hospital and UCL Institute of Ophthalmology, London; and School of
Optometry and Vision Sciences (M.V.), Cardiff University, UK. L.V. is
currently affiliated with the Molecular, Cellular and Developmental Neu-
robiology Department, Cajal Institute-CSIC, Madrid, Spain.
AUTHOR CONTRIBUTIONS
Chunyan Liao: acquisition and analysis of data. Neil Ashley: acquisi-
tion and analysis of data. Alan Diot: acquisition and analysis of data.
Karl Morten: acquisition and analysis of data. Kanchan Phadwal:
acquisition and analysis of data. Andrew Williams: clinical description
of patient. Ian Fearnley: clinical description of patient. Lyndon
Rosser: acquisition and analysis of data. Jo Lowndes: clinical descrip-
tion of patient. Carl Fratter: acquisition and analysis of data. David
Ferguson: acquisition and analysis of data. Laura Vay: acquisition
and analysis of data. Gerardine Quaghebeur: clinical description of
patient. Isabella Moroni: clinical description of patient. Stefania Bianchi:
clinical description of patient. Costanza Lamperti: clinical description of
patient. Susan Downes: clinical description of patient. Kamil S. Sitarz:
acquisition and analysis of data. Padraig J. Flannery: acquisition and anal-
ysis of data. Janet Carver: acquisition and analysis of data. Eszter Dombi:
acquisition and analysis of data. Daniel East: acquisition and analysis of
data. Matilde Laura: characterization of patient cells. Mary M. Reilly:
characterization of patient cells. Heather Mortiboys: acquisition
and analysis of data. Remko Prevo: acquisition and analysis of
10 Neurology 88 January 10, 2017
data. Michelangelo Campanella: acquisition and analysis of data.
Matthew Daniels: acquisition and analysis of data. Massimo Zeviani:
critical revision of the manuscript. Patrick Yu-Wai-Man:
clinical description of patient and critical revision of the manuscript.
Anna Katharina Simon: critical revision of the manuscript. Marcela
Votruba: critical revision of the manuscript. Joanna Poulton: supervisor
role, critical revision of the manuscript, design and conceptualization
of the study.
ACKNOWLEDGMENT
The authors thank the patients and their families for participating, Daniele
Ghezzi for help with bioinformatics, Aviva Tolkovsky for expert advice,
Rebecca Muir and Pippa Oakeshott for proofing, and Stephen Kennedy
for support.
STUDY FUNDING
This work was supported by the Oxford Partnership Comprehensive Bio-
medical Research Centre with funding from the Department of Health’s
NIHR Biomedical Research Centres funding scheme, NewLife, the MRC
(MR/J010448/1), the Wellcome Trust (0948685/Z/10/Z) and the
Angus Memorial Mitochondrial Fund. J.P., J.L., J.C., and C.F. have
salary support from the NHS Specialized Services Rare Mitochondrial
Disorders Service. K.P. and A.K.S. were funded by the NIHR Biomedical
Research Center Oxford. P.Y.-W.-M. is supported by a Clinician Scien-
tist Fellowship Award (G1002570) from the Medical Research Council
(MRC, UK) and receives funding from Fight for Sight (UK), the UK
National Institute of Health Research (NIHR) as part of the Rare Dis-
eases Translational Research Collaboration, and the NIHR Biomedical
Research Centre based at Moorfields Eye Hospital NHS Foundation
Trust and UCL Institute of Ophthalmology. The views expressed are
those of the authors and not necessarily those of the NHS, the NIHR,
or the Department of Health.
DISCLOSURE
C. Liao was funded by the Wellcome Trust (0948685/Z/10/Z).
N. Ashley reports no disclosures relevant to the manuscript. A. Diot
was funded by the MRC (MR/J010448/1) and the NewLife Foundation.
K. Morten was funded by the Williams Foundation. K. Phadwal was
funded by the NIHR Biomedical Research Centre, Oxford. A. Williams,
I. Fearnley, L. Rosser, J. Lowndes, C. Fratter, D. Ferguson, L. Vay,
G. Quaghebeur, I. Moroni, S. Bianchi, C. Lamperti, S. Downes,
K. Sitarz, and P. Flannery report no disclosures relevant to the manu-
script. J. Carver was funded by the MRC (MR/J010448/1). E. Dombi
was funded by the Lily Foundation, the Angus Memorial Mitochondrial
Fund, and the NewLife Foundation. D. East, M. Laura, M. Reilly,
H. Mortiboys, R. Prevo, and M. Campanella report no disclosures relevant
to the manuscript. M. Daniels reports sponsorship from the Wellcome
Trust (WT098519MA). M. Zeviani reports no disclosures relevant to the
manuscript. P. Yu-Wai-Man holds a consultancy agreement with GenSight
Biologics (Paris, France). A. Katharina Simon was funded by the NIHR
Biomedical Research Centre, Oxford. M. Votruba reports no disclosures
relevant to the manuscript. J. Poulton was funded by the Wellcome Trust
(0948685/Z/10/Z), the MRC (MR/J010448/1), Lily Foundation, the
Angus Memorial Mitochondrial Fund, and the NewLife Foundation. Go
to Neurology.org for full disclosures.
Received July 5, 2016. Accepted in final form October 4, 2016.
REFERENCES
1. Gomes LC, Di Benedetto G, Scorrano L. During autoph-
agy, mitochondria elongate are spared from degradation
and sustain cell viability. Nat Cell Biol 2011;13:589–598.
2. Klionsky DJ, Abdelmohsen K, Abe A, et al. Guidelines for
the use and interpretation of assays for monitoring autoph-
agy (3rd edition). Autophagy 2016;12:1–222.
3. Rugarli EI, Langer T. Mitochondrial quality control:
a matter of life and death for neurons. EMBO J 2012;
31:1336–1349.
4. Mortensen M, Ferguson DJ, Edelmann M, et al. Loss of
autophagy in erythroid cells leads to defective removal of
mitochondria and severe anemia in vivo. Proc Natl Acad
Sci USA 2010;107:832–837.
5. Dai Y, Zheng K, Clark J, et al. Rapamycin drives selection
against a pathogenic heteroplasmic mitochondrial DNA
mutation. Hum Mol Genet 2014;23:637–647.
6. Dombi E, Diot A, Morten K, et al. The m.13051G.A
mitochondrial DNA mutation results in variable neu-
rology and activated mitophagy. Neurology 2016;86:
1921–1923.
7. Amati-Bonneau P, Guichet A, Olichon A, et al. OPA1
R445H mutation in optic atrophy associated with senso-
rineural deafness. Ann Neurol 2005;58:958–963.
8. Carelli V, Musumeci O, Caporali L, et al. Syndromic
parkinsonism and dementia associated with OPA1 mis-
sense mutations. Ann Neurol 2015;78:21–38.
9. Longatti A, Orsi A, Tooze SA. Autophagosome forma-
tion: not necessarily an inside job. Cell Res 2010;20:
1181–1184.
10. Korolchuk VI, Saiki S, Lichtenberg M, et al. Lysosomal
positioning coordinates cellular nutrient responses. Nat
Cell Biol 2011;13:453–460.
11. Pesch UE, Leo-Kottler B, Mayer S, et al. OPA1 mutations
in patients with autosomal dominant optic atrophy and
evidence for semi-dominant inheritance. Hum Mol Genet
2001;10:1359–1368.
12. Schaaf CP, Blazo M, Lewis RA, et al. Early-onset severe
neuromuscular phenotype associated with compound het-
erozygosity for OPA1 mutations. Mol Genet Metab 2011;
103:383–387.
13. Yu-Wai-Man P, Griffiths PG, Gorman GS, et al. Multi-
system neurological disease is common in patients with
OPA1 mutations. Brain 2010;133:771–786.
14. Amati-Bonneau P, Valentino ML, Reynier P, et al.
OPA1 mutations induce mitochondrial DNA instabil-
ity and optic atrophy “plus” phenotypes. Brain 2008;
131:338–351.
15. Yu-Wai-Man P, Sitarz KS, Samuels DC, et al. OPA1 mu-
tations cause cytochrome c oxidase deficiency due to loss
of wild-type mtDNA molecules. Hum Mol Genet 2010;
19:3043–3052.
16. Diot A, Hinks-Roberts A, Lodge T, et al. A novel quan-
titative assay of mitophagy: combining high content anal-
ysis fluorescence with mitochondrial DNA mutant load to
identify novel pharmacological modulators of mitophagy.
Pharmacol Res 2015;100:24–35.
17. Sarzi E, Angebault C, Seveno M, et al. The human
OPA1delTTAG mutation induces premature age-
related systemic neurodegeneration in mouse. Brain
2012;135:3599–3613.
18. Ashley N, Harris D, Poulton J. Detection of mitochon-
drial DNA depletion in living human cells using Pico-
Green staining. Exp Cell Res 2005;303:432–446.
19. Uusimaa J, Evans J, Smith C, et al. Clinical, biochemical,
cellular and molecular characterization of mitochondrial
DNA depletion syndrome due to novel mutations in the
MPV17 gene. Eur J Hum Genet 2014;22:184–191.
20. Elachouri G, Vidoni S, Zanna C, et al. OPA1 links human
mitochondrial genome maintenance to mtDNA replica-
tion and distribution. Genome Res 2011;21:12–20.
21. Ashley N, Poulton J. Anticancer DNA intercalators cause
p53-dependent mitochondrial DNA nucleoid re-model-
ling. Oncogene 2009;28:3880–3891.
Neurology 88 January 10, 2017 11
22. Kimura S, Noda T, Yoshimori T. Dynein-dependent
movement of autophagosomes mediates efficient en-
counters with lysosomes. Cell Struct Funct 2008;33:
109–122.
23. Korolchuk VI, Rubinsztein DC. Regulation of autophagy
by lysosomal positioning. Autophagy 2011;7:927–928.
24. Ebneth A, Godemann R, Stamer K, Illenberger S,
Trinczek B, Mandelkow E. Overexpression of tau protein
inhibits kinesin-dependent trafficking of vesicles, mito-
chondria, and endoplasmic reticulum: implications for
Alzheimer’s disease. J Cell Biol 1998;143:777–794.
25. Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira
AH, Taanman JW. Mitofusin 1 and mitofusin 2 are
ubiquitinated in a PINK1/parkin-dependent manner
upon induction of mitophagy. Hum Mol Genet
2010;19:4861–4870.
26. Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selec-
tively stabilized on impaired mitochondria to activate Par-
kin. PLoS Biol 2010;8:e1000298.
27. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is
recruited selectively to impaired mitochondria and pro-
motes their autophagy. J Cell Biol 2008;183:795–803.
28. Carelli V, Sabatelli M, Carrozzo R, et al. “Behr syndrome”
with OPA1 compound heterozygote mutations. Brain
2015;138:e321.
29. Mishra P, Carelli V, Manfredi G, Chan DC. Proteolytic
cleavage of Opa1 stimulates mitochondrial inner mem-
brane fusion and couples fusion to oxidative phosphoryla-
tion. Cell Metab 2014;19:630–641.
30. Olichon A, Landes T, Arnaune-Pelloquin L, et al. Effects
of OPA1 mutations on mitochondrial morphology and
apoptosis: relevance to ADOA pathogenesis. J Cell Physiol
2007;211:423–430.
31. Civiletto G, Varanita T, Cerutti R, et al. Opa1 overex-
pression ameliorates the phenotype of two mitochondrial
disease mouse models. Cell Metab 2015;21:845–854.
32. Bertholet AM, Millet AM, Guillermin O, et al. OPA1 loss
of function affects in vitro neuronal maturation. Brain
2013;136:1518–1533.
33. Gilkerson RW, De Vries RL, Lebot P, et al. Mitochondrial
autophagy in cells with mtDNA mutations results from
synergistic loss of transmembrane potential and mTORC1
inhibition. Hum Mol Genet 2012;21:978–990.
34. White KE, Davies V, Hogan V, et al. OPA1 deficiency is
associated with increased autophagy in retinal ganglion
cells in a murine model of dominant optic atrophy. Invest
Ophthalmol Vis Sci 2009;50:2567–2571.
35. Kim TY, Wang D, Kim AK, et al. Metabolic labeling
reveals proteome dynamics of mouse mitochondria. Mol
Cell Proteomics 2012;11:1586–1594.
36. Twig G, Elorza A, Molina AJ, et al. Fission and selective
fusion govern mitochondrial segregation and elimination
by autophagy. EMBO J 2008;27:433–446.
37. Lemasters JJ. Variants of mitochondrial autophagy: types 1
and 2 mitophagy and micromitophagy (type 3). Redox
Biol 2014;2:749–754.
38. Baloh RH, Schmidt RE, Pestronk A, Milbrandt J. Altered
axonal mitochondrial transport in the pathogenesis of
Charcot-Marie-Tooth disease from mitofusin 2 mutations.
J Neurosci 2007;27:422–430.
39. Tondera D, Grandemange S, Jourdain A, et al. SLP-2 is
required for stress-induced mitochondrial hyperfusion.
EMBO J 2009;28:1589–1600.
40. Giordano C, Iommarini L, Giordano L, et al. Efficient mito-
chondrial biogenesis drives incomplete penetrance in Leber’s
hereditary optic neuropathy. Brain 2014;137:335–353.
12 Neurology 88 January 10, 2017
DOI 10.1212/WNL.0000000000003491
 published online December 14, 2016Neurology 
Chunyan Liao, Neil Ashley, Alan Diot, et al. 
mutations
OPA1Dysregulated mitophagy and mitochondrial organization in optic atrophy due to 
This information is current as of December 14, 2016
Services
Updated Information &
003491.full.html
http://www.neurology.org/content/early/2016/12/14/WNL.0000000000
including high resolution figures, can be found at:
Supplementary Material
0003491.DC1.html
http://www.neurology.org/content/suppl/2016/12/14/WNL.000000000
Supplementary material can be found at: 
Subspecialty Collections
_genetics-mitochondrial_disorders
http://www.neurology.org//cgi/collection/mitochondrial_disorders_see
Mitochondrial disorders; see Genetics/Mitochondrial disorders
http://www.neurology.org//cgi/collection/mitochondrial_disorders
Mitochondrial disorders
following collection(s): 
This article, along with others on similar topics, appears in the
 
Permissions & Licensing
http://www.neurology.org/misc/about.xhtml#permissions
its entirety can be found online at:
Information about reproducing this article in parts (figures,tables) or in
 
Reprints
http://www.neurology.org/misc/addir.xhtml#reprintsus
Information about ordering reprints can be found online:
ISSN: 0028-3878. Online ISSN: 1526-632X.
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print
1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2016 The Author(s). Published by 
® is the official journal of the American Academy of Neurology. Published continuously sinceNeurology 
                                                                        Liao et al  supplementary information page 1
 
Supplementary information 
 
Appendix e-1: Supplementary clinical and molecular information (see 
table 1) 
Family 1 Clinical presentation  
DOAplus OPA1(-/-)1 is a 17 year old Caucasian male from the UK, who presented with a 
severe phenotype due to OPA1 at the age of 10.  As well as clumsiness and progressive 
unsteadiness, his mother reported worsening school performance and painful parasthesiae in 
his limbs.  He admitted to loss of sensation in his hands and feet.  He had developed poor 
vision in infancy, presenting aged 10 months with a convergent squint and corrective 
surgery aged 14 months.  At aged 2 he was bumping into things, with progressive stepwise 
visual loss over 8 months.  There was no relevant family history (Figure 1A). 
 
On examination, he was a well grown boy without dysmorphic features.  He had bilateral 
optic atrophy,  but no ptosis and full eye movements.  Visual acuities were finger counting 
in the left eye and less than this in the right.  Flash electroretinograms indicated normal 
photoreceptor/outer retinal function, and visual evoked potentials were consistent with 
abnormal optic nerve conduction.  Muscle bulk and power were normal, but with distal 
laxity in the upper limbs. In the lower limbs, he had slightly decreased ankle dorsiflexion 
and his reflexes were brisk with ankle clonus.  He also had reduced sensation in all 
modalities tested, suggesting a sensory neuropathy.  He was unsteady on his feet, but had no 
evidence of cerebellar ataxia. Cranial MRI (see below) showed very small optic nerves and 
chiasma.  Electrophysiology showed an axonal neuropathy affecting sensory fibres more 
than motor.  He subsequently continued to regress, developed epilepsy, and at 17 years is 
unable to walk independently.  Neuropathic pain is now a major management problem and 
very recently he has developed gastrointestinal problems which are reported separately (1). 
 
Both history and clinical examination of the proband’s mother (N1, carrying c.661G>A 
p.E221K) and grandfather (OPA1(+/-)1 carrying c.2708_2711delTTAG OPA) were 
unremarkable, though the latter did not attend specialist ophthalmology appointments.  The 
latter mutation has a known penetrance of approximately 55% (2).  
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Mitochondrial investigations, including blood and CSF lactate, muscle biopsy COX 
histochemistry and respiratory chain function, were normal.   Mitochondrial DNA mutations 
were excluded, including screening skeletal muscle for mtDNA rearrangements by LPCR 
and full mtDNA sequencing.  MtDNA copy number in skeletal muscle was 115% of 
expected and in fibroblasts 94%.  In addition, nuclear DNA sequencing excluded mutations 
in the whole of the POLG  and the mutation hotspot of the PEO1 (TWINKLE) genes.  The 
absence of mtDNA abnormalities seen in CPEO patients is probably because of his youth, 
and the normal respiratory chain results do not conflict with the subtle defects identified by 
others (33-37)  (3). 
 
Family 2 Clinical presentation 
The proband, DOAplus OPA1(-/-)2, is a girl, now 12 years old, with a severe and 
progressive visual defect, born to non consanguineous Italian parents.  Family history was 
negative for neurological and ophthalmologic diseases.  Pregnancy and delivery were 
uneventful; psychomotor development was reported to be normal. Parents suspected poor 
vision from 3 years of age; the first ophthalmologic examination, at 6 years of age, 
confirmed a severe loss of visual acuity. Brain MRI was normal; visual evoked potentials 
revealed markedly reduced amplitudes; ERG was unremarkable. When first observed by us, 
at 8 years of age, the ophthalmologic evaluation revealed a marked pallor of the optic disc. 
Neurological examination showed bilateral pes cavus and reduced tendon reflexes in lower 
limbs, but no motor symptoms.  EMG showed a reduction of Sensory Action Potentials in 
her lower limbs (6.0 V in peroneal nerves) with normal Sensory Conduction Velocities. 
 
The brother, OPA1(-/-)3, now aged 6 years and 10 months, had an identical course to his 
sister.  He was noted to have difficulties in watching the television since the second year of 
life.  He was examined at 4 years of age and showed the presence of similar ophthalmologic 
signs (reduced visual acuity, and pale optic discs at fundus exam), without signs of 
neurological impairment. At the last observation at 6.5 years of age he also showed bilateral 
pes cavus with mild reduction of distal tendon reflexes in his lower limbs. Plasma lactate 
and pyruvate were both normal in both siblings.  
 
The neurological and ophthalmological examination of both parents was normal at first 
consultation (father is designated N2 and the mother OPA1(+/-)2 ).  At the last examination, 
the mother (aged 41) showed mild signs of optic atrophy, and a pathologically thin retinal 
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nerve fibre layer by optical coherence tomography retinal imaging.  The father (aged 47) 
remains entirely normal.  Recently a maternal aunt reported a visual defect.   
 
Figure e-1A:  MRI scan of patient DOAplus OPA1(-/-)1 
MRI scan showed bilateral degeneration of the optic nerves (red arrows) which are very 
small.  Proband on left, age matched “control” on right. 
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Figure e-1B 
Further information about OPA1 variants identified in patients whose cell cultures 
were analysed in detail including protein alignments.   
OPA1 sequence was used for the organisms listed, except for D.Melanogaster, A.Gambiae 
and C.Elegans where Opa1-like, AgaP_AGAP011286 and EAT-3  were used respectively.  
In D.Rerio, Opa1-like was used in addition to OPA1.  In the bottom panel, the substituted 
residues are highlighted in yellow.  
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Figure e-2.  Validation of  ImageStream and further validation of INCell 1000 for 
detecting mitophagy  
 
Figure e-2A  Confocal imaging of mitophagy 
Mouse embryonic fibroblasts expressing both dsred targeted to mitochondria and LC3 tagged 
with GFP were grown in regular medium (glucose) or in the presence of lysosomal inhibitors 
E64d and pepstatin A (Glucose E&P).  After fixation, mitochondrial (dsred) and 
autophagosomes (GFP) signals were acquired on a Leica SP5 confocal microscope using a 
63X lens and further digital zoom when needed.  Arrowheads indicate autophagosomes 
engulfing mitochondria ie mitophagy (Glucose E&P zoomed in bottom panels). 
 
Figure e-2B Mitophagy events per cell corresponding to the confocal images in part A 
were quantitated using IN Cell 1000. 
This additional validation of IN Cell 1000 shows a significant increase in co-localisation of 
LC3 puncta with mitochondria in the presence of E64d and pepstatin A (E+P). 
 
Figure e-2C Raw ImageStream output displaying 4 views on one gated cell.  Channel 05 
(Left) shows fibroblasts in bright field, channel 03 detects mitochondrial signal (PDH, 
Mitoscience) and channel 06 detects LC3 (Cell Signalling Technology), using anti-mouse 
Alexa-488 and anti-rabbit Alexa -546 secondary antibodies respectively (both Invitrogen).  
Ch03/Ch06 shows co-localisation of bright signal.  
 
 
Figure e-2D: Using IN Cell 1000 to validate ImageStream 
 Cells that have been well characterised by confocal microscopy (4) were used to 
Validate ImageStream (right chart) against IN Cell 1000 (left chart).   These cells are HeLa 
cells expressing dsred targeted to mitochondria and GFP-tagged either autophagosome 
marker LC3 or lysosomal marker CD63 (courtesy of Prof A Tolkovsky (4)).  Figures 9 and 
10 of that paper (4) follow mitophagy in real time by co-localisation of the mitochondrial 
dsred with these markers.   Counts of GFP puncta (either LC3-labelled autophagosomes 
shown on the left of each plot, or autolysosome labelled with CD63 shown on the right of 
each plot) that are co-localised with mitochondria, thus reflect sequential stages of 
mitophagy.  In corresponding ImageStream (C) and IN Cell 1000 experiments (D), the bar 
chart shows co-localisation of GFP puncta with mitochondrial (dsred) signal at baseline, in 
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the presence of either 3 days glucose-free galactose media (Gal) or following 16 hours 
exposure to chloroquine 25 μM (Glu CQ).  Chloroquine substantially increases the number 
of autophagosomes but not autolysosomes, galactose causes a more modest increase.  The 
results in (C) and (D) look very similar, suggesting that both techniques are able to measure 
co-localisation of mitochondria with GFP puncta. 
Error bars are standard errors of technical replicates.   
 
Figure e-2E  Knock out of the essential mitophagy protein, Atg7, in mouse splenocytes 
reduces co-localisation of LC3 and LyosID positive puncta with mitochondria, further 
validating the ability of ImageStream to detect mitophagy. 
 
To validate that ImageStream is able to detect mitophagy we investigated mouse 
splenocytes, obtained from either wild type mice or from mice whose key autophagy gene, 
Atg7, has been excised in the haematopoietic system only (Vav-Atg7-/-) (5) (6).   
All animal studies were carried out with approval of the Local Ethical Review Panel at the 
University of Oxford under license in accordance with the UK Animals (Scientific 
Procedures) Act 1986.   
 
Left panel:  The number of LC3 positive puncta co-localising with mitochondrial signal at 
baseline and after Chloroquine (25 μM chloroquine overnight) was decreased in Atg7 deficient 
mouse splenocytes (Atg7 KO, P<0.01).    
Right panel: Puncta that were both positive for LC3 and lysosomal marker, LysoID and co-
localised with mitochondria were counted to estimate the effects of Atg7 knockdown on 
numbers of autolysosomes.  These were reduced in splenocytes from the Atg7 knockout 
(p<0.01).  NB  Chloroquine prevents lysosomal maturation by inhibiting acidification.  
Hence while it substantially increases the number of autophagosomes (ie of all LC3 positive 
puncta) co-localising with mitochondria (left) it does not much affect the counts of autolysomes 
co-localising with mitochondria (right). 
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Figure e-2 
A)  
 
      
 
Supplementary 
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Figure e-3. 
Addition cellular features of OPA1 knock down.   
Figure e-3A  Confirmation of increased mitochondrial fragmentation in bi-allelic 
patient fibroblasts using ImageStream output, aspect ratio (the minor axis divided by 
the major axis, describes how round or oblong an object is, being 1.0 for a circle and 
lower for elongated objects) of mitochondria was determined from ImageStream 
output (using a mitochondrial mask based on an intensity threshold of 30%, see 
methods).  The difference between aspect ratio of each patient group and controls is shown 
as the Y axis in the chart.  We show one bar per patient group, with each bar's height 
representing the estimated difference between a particular patient group and controls. The 
whiskers on a bar represent the standard error (SE) of the estimated difference (+/- 1 SE is 
shown); an approximate 95% confidence interval for the patient-control difference could be 
calculated as the bar height +/- 2 SEs.  The p-values in the figure are from the test of the null 
hypothesis that there is no actual difference between a patient group and controls. In eight 
experiments involving individuals listed in Table 1 and six controls, mitochondria in 
fibroblasts from bi-allelic and mono-allelic DOA plus patients are significantly more 
fragmented than mitochondria from controls (p=0.005 and 0.01 respectively).  There was no 
significant difference between non-syndromic patients and controls.  
 
Figure e-3B  Microtubule dependence of the perinuclear mitochondrial clustering 
resulting from profound OPA1 knock down that was demonstrated in Figure 2: 
Dynein disruption by overexpression of p50-dynamitin-GFP rescues mitochondrial 
MTOC clustering due to loss of Opa1.   
 
We hypothesized that clustering of mitochondria at the MTOC in KD cells may be due to 
either an imbalance of plus- and minus-end transport caused by excessive fragmentation and 
mitophagy or a hitherto unknown role of Opa1 in promoting plus-end directed transport of 
mitochondria.  In either case, loss of Opa1 would cause a preponderance of negative-end-
directed transport of mitochondria along microtubules towards the MTOC, leading to 
perinuclear clustering. Figure 2F illustrates how we tested this idea, by exposing cells to two 
microtubule-disrupting drugs: nocodazole and taxotere. Nocodazole causes the disassembly 
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of microtubules, whereas taxotere causes MTOC-independent, random assembly and 
stabilization of microtubules(7) that lack polarity and orientation(8). Treatment of Opa1 KD 
cells with nocodazole rescued the perinuclear clustering so that the distribution of 
mitochondria resembled that in control cells (Figure 2F(ii)). In contrast, taxotere treatment led 
to the formation of multiple, randomly distributed mitochondrial clusters. Finally, we also 
tested the role of actin filaments in Opa1 KD-mediated mitochondrial clustering by using the 
actin depolymerising drug cytochalasin D. As with nocodazole, treatment of KD cells with 
cytochalasin D caused a redistribution of mitochondria away from the MTOC, although weak 
perinuclear clustering was still observed in some cells.  In all cases, treatment of scramble 
siRNA transfected cells with drugs had little effect on mitochondria (data not shown).  These 
experiments confirm that the organization of MTOC and microtubules are pivotal to and 
upstream of the mitochondrial clustering caused by Opa1 KD.  To determine which transport 
direction was involved we investigated the dynein/dynactin multi-protein complex(9) that 
mediates minus-end–directed transport of mitochondria. Overexpression of a GFP-tagged 
dynactin sub-unit (p50/dynamitin), disrupts the dynein/dynactin complex, leading to loss of 
minus-end transport(10, 11), which in turn is known to disrupt autophagy(12),(13).  
Mitochondrial clustering was apparent with TMRM staining of OPA1 siRNA treated cells 
transfected with pcDNA plasmid (control, lower panel), but not in those transfected with the 
p50 dynamitin GFP expressing plasmid (upper panel).  Nuclei are marked by asterisks. This 
shows that clustering is rescued by p50 dynamitin GFP expression and therefore depends on 
minus-end microtubule transport.  Mitochondrial distribution was not affected when the same 
transfections were carried out with scramble siRNA treatment.  
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Figure e-4 
e-4A Mitophagic flux is increased in fibroblasts of bi-allelic patients 
 
Co-localisation of mitochondria with LC3 positive puncta was quantified in fibroblasts from 
patient DOAplus OPA1(-/-)1 and two controls using IN Cell 1000 as above.  Flux (defined 
as the increase in co-localisation relative to baseline) was greater in the patient than the 
controls  (p<0.001 at 24h) and increased appropriately over 24 hours.   
e-4B Idebenone does not ameliorate the increased mitophagy in fibroblasts of bi-allelic 
patients 
Co-localisation of mitochondria with LC3 positive puncta (expressed as mitophagy area as a 
percentage of mitochondrial area) in glucose-based media was not affected by 3 days 
exposure to idebenone 1uM for 72h (error bars are standard errors of technical replicates).  
This reflects idebenone treatment the animal model, in which there was no improvement 
(14). 
 
Figure e-4A 
 
 
Figure e-4B 
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Figure e-5 Western analysis of fibroblast protein 
A  Western blot analysis of OPA1, p62 and LC3 proteins relative to actin in OPA1 mutant 
fibroblasts of patients DOAplus OPA1(-/-)1-3 and mitofusin 2 (MFN2) mutant fibroblasts 
compared to control.  Cells were grown either in regular medium (Glu) or glucose-free 
galactose-based medium (Gal) for 48 hours. 
B  The abundance of summed OPA1 short and long isoforms (15) are reduced in the 
patients relative to the average control (Ave).   
C  LC3-II abundance (relative to actin) is increased in fibroblasts from patients 
DOAplusOPA1(-/-)2 and 3 but not DOAplusOPA1(-/-)1 compared to control  
D  Western blot analysis of OPA1 relative to GAPDH in OPA1 mutant fibroblasts of 
patients DOAplus OPA1(+/-)1 and  DOA OPA1(+/-) show a reduction in OPA1 abundance. 
E   Western blot analysis of OPA1 and LC3 proteins relative to actin in OPA1 mutant 
fibroblasts of patient DOAplus OPA1(-/-)1 and his unaffected mother (N1) and unaffected 
grandfather (OPA1(+/-)1) compared to control.  The lower OPA1 band correspond to the 
short (s-OPA1) and the upper two bands to the long (l-OPA1) isoforms (15).   The levels of 
OPA1 both short and long forms are reduced in the patient and carrier grandfather relative to 
the control.  LC3-I and LC3-II are increased in patient 1 but not his unaffected carrier 
grandfather compared to control. 
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Figure e-5. 
   E 
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Figure e-6.  OPA1 loss in fibroblasts leads to mitochondrial fragmentation without loss 
of cytochrome c or alteration of cristae.  
 
a) Cytochrome c/Mitotracker red staining of fibroblasts treated with pan-OPA1 or scrambled 
siRNA for 48 hours. There was no leakage of cytochrome c from mitochondria, [Bars 
10μM]  
b) Electron micrographs of mitochondria from control (left) and pan-OPA1/scrambled 
siRNA treated (right) fibroblasts showing the similar appearance of the mitochondrial 
cristae. [Bars 200 nm].  There was no gross increase in autophagosomes as seen by EM. 
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Figure e-7 
 
Illustration of suggested sequence of events 
The diagram illustrates the sequence of events that may be occurring in affected tissue with 
increasingly severe depletion of full length OPA1.  The first four stages are apparent in 
fibroblasts from patients.  The portion indicated by the dotted arrow illustrates our postulate 
that mtDNA depletion causes significant mitochondrial dysfunction in some tissues, as is 
apparent in siRNA of control fibroblasts.  That neurodegeneration is a direct consequence of 
this process is unproven. 
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Appendix e-2: Supplementary methods 
 
Cell cultures (see Table 1) 
Patient cultures 
It is generally accepted that primary patient fibroblasts express both OPA1 protein 
deficiency(16) and defects in autophagy(17), and are hence appropriate for pathophysiological 
investigations.  By characterising fibroblasts from four of the healthy or oligosymptomatic 
transmitting relatives of the three bi-allelic patients, we were able to study each of their OPA1 
mutations in mono-allelic cultures.  Three DOA patients with dominantly inherited mutations 
in the OPA1 GTPase domain were studied, of whom one had uncomplicated DOA, and two 
had DOA plus (DOA OPA1(+/-), DOAplusOPA1(+/-)1  and DOAplus OPA1(+/-)2 
respectively, see Table 1).   
Disease control culture 
One fibroblast line from a patient with severe symptomatic dominantly inherited axonal 
Charcot-Marie-Tooth disease CMT2A2 due to the c.745T>A (p.Ser249Thr) in the large 
GTPase domain near the N-terminus of mitofusin 2 was used (MFN2).   
Control cultures 
Twenty anonymised control fibroblast cultures were used for comparison (designated 
“control” and not including unaffected family members whose designations are in Table 1), 
taken (i) with parental consent from children undergoing diagnostic skin biopsy for 
karyotyping or biochemical screen and where cytogenetics or similar was normal (n=2), and 
(ii) from healthy consented adults.  The age range was thus 0-81 years.  One control at the 
median mitophagic activity, whose age was within 3 years of patient DOAplus OPA1(-/-)1 
was included in the vast majority of runs.   
Cells with fluorescent organelles 
To validate our methods we also used cultured cells with fluorescent mitochondria and 
autophagosomes or autolysosomes.  These were HeLa cells expressing dsred targeted to 
mitochondria and GFP tagged either LC3 or the lysosomal marker CD63 (4) (courtesy of 
Aviva Tolkovsky).  For comparison with a related defect in mitochondrial dynamics we also 
used cultures from a patient with MFN2 mutations.   
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Immunofluorescence and live cell imaging 
Cells were processed for histochemistry(18), immunofluorescence or live staining with 
PicoGreen and TMRM as previously described(19). For fluorescence microscopy the 
antibodies used were: Anti-cytochrome c (Clone 6H2.B4, Biolegend); Anti-DNA IgM (Peter 
Cook); OPA1 (Clone 18, BD Biosciences); Anti-pericentrin (ab4448, AbCam); and Anti-
GM130 (clone EP892Y, AbCam).  MtDNA staining in live cells was achieved by diluting 
stock PicoGreen solution at 3µl/ml (2 hours), then rinsed 3 times in pre-warmed PBS and 
mounted with phenol red free DMEM supplemented with 4.5g/l glucose and 25mM HEPES 
buffer, and visualised using a Leica DMI50 microscope. Mitochondrial co-labelling was 
achieved by incubating the cells in fresh medium containing 50nM Mitotracker red for 5 
minutes before rinsing with fresh medium. Tetramethylrhodamine methyl ester (TMRM) 
staining was used to monitor mitochondrial membrane potential. Cells were incubated for 20 
minutes in medium containing 50nM TMRM at 37oC and visualised without removal of the 
dye.  
 
IN Cell 1000 high throughput imaging (20). 
We previously validated IN Cell 1000 for detecting mitophagy (20).  In brief, cells are cultured 
in a 96-well plate and treated for 6 hours in the indicated conditions before fixation with 4% 
paraformaldehyde (PFA). After DAPI and immuno-staining using a monoclonal antibody 
anti-TOM20 (Santa Cruz Biotechnology, mouse) and a polyclonal antibody anti-LC3 
(Medical and Biological Laboratories, rabbit) combined to Alexa Fluor 488 Goat anti-rabbit 
and Alexa Fluor 568 Goat anti-mouse (life technologies) secondary antibodies the plate is 
imaged using the IN Cell1000 analyser (GE healthcare life sciences, 500 cells per well). Raw 
images were binarised and mitochondrial morphological characteristics were quantified, notably 
the degree of branching or mitochondrial form factor (FF) and the mean mitochondria length 
(in m).  
Figures e-2A and e-2B show a comparison of IN Cell 1000 output with confocal microscopy, 
using mouse embryonic fibroblasts  in which dsred is targetted to mitochondria and GFP to 
autophagosomes by tagging LC3.   Exposure to lysosomal inhibitors E64d and Pepstatin A 
increases the co-localisation of mitochondria with autophagosomes by both techniques, 
microscopy showing that the mitochondrial fragments are engulfed. 
 
ImageStream validation for analysis of mitophagy 
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We also used ImageStream (Amnis) to quantify mitophagy in fibroblast cultures from 
patients and controls.  This was previously validated as a method for detecting autophagy (21)  
 
Primary cell cultures were harvested, washed in PBS, and fixed with 4% paraformaldehyde 
for 15 minutes at room temperature and permeabilized by adding 0.4% triton to the fixative 
for 5 minutes.  They were then immunostained with antibodies to the E1 α subunit of PDH 
(Mitoscience) or LC3 (Cell Signalling Technology) followed by anti-mouse Alexa-488 and 
anti-rabbit Alexa-546 secondary antibodies respectively (Invitrogen), counting 1000-5000 
cells in each condition on each of three occasions.  An example of raw output from 
ImageStream is shown in Figure e-2C. 
 
To identify co-localisation of autophagosomes and mitochondria as an indicator of mitophagy 
we used Amnis IDEAS software.  Initially we quantitated bright detail similarity (BDS) of 
mitochondrial and LC3 signals.   BDS is a feature that calculates the degree of overlapping 
pixel intensities taken from different channels of fluorescent imagery and is the log-
transformed Pearson’s correlation coefficient that is non mean normalized.  It is applied either 
to the open residue image or to a masked image designed to detect LC3 puncta (spots of ~1 
μm with an LC3 intensity that contrasted with the rest of the cell by more that 3-6 fold basal 
intensity).  However, we found that counting the numbers of LC3/LysoID positive puncta was 
more robust than using BDS, especially in runs with a relatively high background.  As well as 
the total number of such spots per cell, we compared the number of LC3/lysoID positive 
puncta that co-localized with mitochondria, using a “threshold” mask detecting mitochondrial 
location.  The threshold mask is used to exclude pixels, based on a percentage of the range of 
intensity values as defined by the starting mask.  We routinely counted the numbers of LC3 
puncta co-localising with the mitochondrial signal, defined by using thresholds at both 30% 
and 70% of the mitochondrial signal intensity.  For these features to be accurate, it is essential 
to gate on cells that are bright for both fluorescent markers of interest (double positive 
population). 
 
We used ImageStream for a small proportion of our experiments as we found that IN Cell 
1000 was superior in its resolution, cost and reliability.  Figure e-2D shows that the output 
of this method correlates closely with that of IN Cell 1000, which we had validated for 
detecting mitophagy(20).  We further validated ImageStream for detecting mitophagy by 
knocking down the essential autophagy protein, Atg7 in mouse splenocytes (Figure e-2E).  
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ImageStream and IN Cell 1000 shares a significant advantage over older methods for 
detecting both autophagy and mitophagy: both are high throughput techniques that are both 
objective and quantitative (figure e-2 compares them with confocal microscopy).  However, 
we were unable to detect PINK or Parkin signal using either method, nor could we follow 
single autophagosome events in real time.  To our knowledge ImageStream has not 
previously been used to investigate mitophagy in detail.   
 
Quantifying form factor and autophaghic flux with ImageStream and IN Cell 1000 
 
FF is defined as (Pm2)/(4Am), where Pm is the length of mitochondrial outline and Am is 
the area of mitochondrion(22), and with a value comprised between 1 (fragmented network in 
individual dots) and 0 (infinitely connected network). Mitochondria with a FF >0.8 are 
fragmented and their proportion is calculated among all the mitochondria identified.  For 
ImageStream output this was determined from output using a threshold  of 30% for intensity 
of PDH signal. 
 
In order to detect the autophagic flux, we used the lysosomal protease inhibitors pepstatin A 
and E64D, or chloroquine that blocks lysosomal acidification (either 25μM overnight or 10-
100μM for 2 hours).  Autophagy inducing protocols were starvation (minimal media for 2 
hours), or culture in galactose-based media lacking glucose for 12-72 hours.(23, 24).  
Autophagic flux was defined as the difference between lysosomal inhibitors added and no 
lysosomal inhibitors added (basal levels) relative to basal levels(24).  So we defined 
mitophagic flux similarly, as the difference between mitophagy with lysosomal inhibitors 
added and no lysosomal inhibitors added (basal levels) relative to basal levels in mitophagy 
with inhibitors minus without inhibitors over basal levels (Figure 3D and figure e-2E). 
 
Figure e-2D illustrates ImageStream output from primary cells stained for LC3 and pyruvate 
dehydrogenase.  Starvation (either minimal or galactose medium) or the presence of lysosomal 
inhibitors reproducibly increased co-localisation of mitochondrial signal with LC3 puncta 
(Figure 3A shows patient and age-matched control in galactose medium).   
 
Chloroquine inhibits autophagy and hence reproducibly increased the number of LC3 puncta 
per cell as well as bright detail similarity (BDS, a score of the co-localisation of two markers 
in puncta where mitochondrial and LC3 signal co-localised), co-localised spot intensity and 
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co-localised spot count (Figure 3B, p<0.001).  Furthermore it could be inhibited knock 
down of autophagy protein ATG7 (figure e-3A). 
 
Western blotting 
2x105 cells were seeded in the plate and grown at 37oC overnight.  Cells were washed twice 
in cold PBS and harvested in 50ul 1X Laemmli sample buffer. The cells were then  lysed by 
pulsing the sonicator for 5 seconds on/5 seconds off, twice, heated at 95°C for 5mins, and 
centrifuged at 15700g for 1 minute. 10ul of the supernatant were loaded on to a 4-20% gel for 
SDS-PAGE. Protein was separated by electrophoresis at 125V for 2 hours (Figure 3).  The 
LC3 antibody was from MBL International Corporation (Cat. No: PM036). The OPA1 
antibody was from BD transduction laboratories (Cat. No: 612606). The P62 antibody is from 
BD transduction laboratories (Cat.No: 610832).  The actin antibody is from cell signalling 
(Cat. No:  11/2011). 
 
 
Electron Microscopy 
The cell pellets were fixed in 2.5 % glutaraldehyde in 0.1M phosphate buffer, post-fixed in 
osmium tetroxide, dehydrated and embedded in epoxy resin. Thin sections were cut and 
stained with uranyl acetate and lead citrate prior to examination in a Jeol 1200EX electron 
microscope. 
 
RNAi and Plasmid Transfections 
RNAi for OPA1 was carried out as previously (25) using 50nM siRNA control and target 
Dharmacon 1 transfection agent (Thermo-Fisher).  The ATG7 siRNA used SMARTpool: ON-
TARGETplus from Thermo scientific, Cat: L-020112-00-0005, Scramble siRNA: 
siGENOME Non-Targeting, Thermo scientific, Cat:# D-001210-02-05A.   
 
Statistical Analysis 
ImageStream output (such as the mean number of LC3 puncta co-localising with 
mitochondria, the number of cells and standard deviation) from eight experiments involving 
individuals listed in Table 1 and five controls was analysed using R version 2.15.2 (the R 
Foundation for Statistical Computing).  The components of the regression equation were: 
Patient ID, run ID and patient group.    Separate analyses were run by grouping patients in 
different ways, and for each analysis each patient group was compared to the controls.  In 
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this way we determined the relationship between genotype and cellular phenotype of the 
patient cultures in the presence or absence of chloroquine. 
Figures 1D and 2C contain one bar per patient group, with each bar's height representing the 
estimated difference between a particular patient group and controls. The whiskers on a bar 
represent the standard error (SE) of the estimated difference (+/- 1 SE is shown); an 
approximate 95% confidence interval for the patient-control difference could be calculated 
as the bar height +/- 2 SEs.  
 
The p-values in the figure are from the test of the null hypothesis that there is no actual 
difference between a patient group and controls. Useful intuition connecting the hypothesis 
test with the estimated difference is that a p-value < 0.05 corresponds to a 95% confidence 
interval not overlapping zero. 
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